{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:18:55Z","timestamp":1787631535884,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.biopha.2023.115149","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:49:27Z","timestamp":1692726567000},"page":"115149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients \u2013 A review"],"prefix":"10.1016","volume":"166","author":[{"given":"Mi\u0142osz","family":"Miedziaszczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Idasiak-Piechocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2023.115149_bib1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.nefro.2018.11.009","article-title":"Envarsus, a novelty for transplant nephrologists: Observational retrospective study","volume":"39","author":"Franco","year":"2019","journal-title":"Nefrologia"},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","article-title":"Tacrolimus oral bioavailability doubles with coadministration of ketoconazole","volume":"62","author":"Floren","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2023.115149_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.1996.tb00181.x","article-title":"Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes","volume":"41","author":"Christians","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115149_bib4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/FTD.0b013e318271b6e6","article-title":"Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole","volume":"34","author":"Zhao","year":"2012","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.biopha.2023.115149_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2133\/dmpk.22.441","article-title":"Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient","volume":"22","author":"Takahashi","year":"2007","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.biopha.2023.115149_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","article-title":"Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics","volume":"22","author":"Iwasaki","year":"2007","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.biopha.2023.115149_bib7","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2023.115149_bib8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0090-9556(25)06862-X","article-title":"Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability","volume":"23","author":"Lampen","year":"1995","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.biopha.2023.115149_bib9","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/TP.0000000000000351","article-title":"Filho, The serum concentration of tacrolimus after ingesting omeprazole: a pilot study","volume":"98","author":"Peloso","year":"2014","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.biopha.2023.115149_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061247","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy in heart transplantation: new strategies and preliminary results in endomyocardial biopsies","volume":"14","author":"De Gregori","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2023.115149_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40780-022-00256-9","article-title":"Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation","volume":"8","author":"Katada","year":"2022","journal-title":"J. Pharm. Health Care Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern. Med."},{"issue":"5","key":"10.1016\/j.biopha.2023.115149_bib13","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1053\/j.ajkd.2017.02.003","article-title":"AJKD atlas of renal pathology: calcineurin inhibitor nephrotoxicity","volume":"69","author":"Lusco","year":"2017","journal-title":"Am. J. Kidney Dis."},{"issue":"9","key":"10.1016\/j.biopha.2023.115149_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091755","article-title":"Insights into the pharmacogenetics of tacrolimus pharmacokinetics and pharmacodynamics","volume":"14","author":"Brunet","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.biopha.2023.115149_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111128","article-title":"The tacrolimus metabolism rate influences renal function after kidney transplantation","volume":"9","author":"Tholking","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12519-018-0125-y","article-title":"Calcineurin inhibitors and nephrotoxicity in children","volume":"14","author":"Liu","year":"2018","journal-title":"World J. Pediatr."},{"issue":"10","key":"10.1016\/j.biopha.2023.115149_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102154","article-title":"Controversial interactions of tacrolimus with dietary supplements, herbs and food","volume":"14","author":"Miedziaszczyk","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jcpt.13256","article-title":"Marked decrease of tacrolimus blood concentration caused by compound Chinese herbal granules in a patient with refractory nephrotic syndrome","volume":"46","author":"Yang","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2023.115149_bib19","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/j.transproceed.2014.01.021","article-title":"Case report: boldo (Peumus boldus) and tacrolimus interaction in a renal transplant patient","volume":"46","author":"Carbajal","year":"2014","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.biopha.2023.115149_bib20","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00228-013-1537-1","article-title":"Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome","volume":"69","author":"Hou","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115149_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00228-005-0952-3","article-title":"Effects of berberine on the blood concentration of cyclosporine A in renal transplanted recipients: clinical and pharmacokinetic study","volume":"61","author":"Wu","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115149_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/01.tp.0000194861.59543.b9","article-title":"Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient","volume":"81","author":"Moreau","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.biopha.2023.115149_bib23","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1016\/j.transproceed.2005.09.126","article-title":"Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study","volume":"37","author":"Pascual","year":"2005","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.biopha.2023.115149_bib24","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.108.025833","article-title":"Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients","volume":"37","author":"Hosohata","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115149_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1399-3046.2011.01559.x","article-title":"A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient","volume":"16","author":"Maguire","year":"2012","journal-title":"Pediatr. Transpl."},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1124\/dmd.112.047977","article-title":"Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285","volume":"41","author":"Boso","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115149_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CEG.S23926","article-title":"Efficacy of esomeprazole in treating acid-related diseases in Japanese populations","volume":"5","author":"Sugimoto","year":"2012","journal-title":"Clin. Exp. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib29","article-title":"Impact of pharmacogenetics on intravenous tacrolimus exposure and conversions to oral therapy","volume":"28","author":"Pasternak","year":"2022","journal-title":"Transpl. Cell Ther."},{"issue":"9","key":"10.1016\/j.biopha.2023.115149_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.5414\/CP202152","article-title":"The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients","volume":"53","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2023.115149_bib31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.clinthera.2020.07.016","article-title":"Effect of ABCB1 3435C>T genetic polymorphism on pharmacokinetic variables of tacrolimus in adult renal transplant recipients: a systematic review and meta-analysis","volume":"42","author":"Peng","year":"2020","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2023.115149_bib32","first-page":"4195","article-title":"Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (\u2011806C>T) alleles among an Iranian population of different ethnicities","volume":"17","author":"Dehbozorgi","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2023.115149_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40264-022-01181-4","article-title":"Incidence, pathogenesis, and management of proton pump inhibitor-induced nephrotoxicity","volume":"45","author":"Wei","year":"2022","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib34","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.9778\/cmajo.20140074","article-title":"Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study","volume":"3","author":"Antoniou","year":"2015","journal-title":"CMAJ Open"},{"issue":"5","key":"10.1016\/j.biopha.2023.115149_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1440-1797.2006.00651.x","article-title":"Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases","volume":"11","author":"Simpson","year":"2006","journal-title":"Nephrology"},{"issue":"5","key":"10.1016\/j.biopha.2023.115149_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cgh.2005.11.004","article-title":"Proton pump inhibitors and acute interstitial nephritis","volume":"4","author":"Geevasinga","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115149_bib37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/phar.2235","article-title":"Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study","volume":"39","author":"Hart","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jgh.15151","article-title":"Acute kidney injury following the use of different proton pump inhibitor regimens: a real-world analysis of post-marketing surveillance data","volume":"36","author":"Chen","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2023.115149_bib39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2369-14-150","article-title":"Proton pump inhibitors and acute kidney injury: a nested case-control study","volume":"14","author":"Klepser","year":"2013","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.biopha.2023.115149_bib40","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2147\/DDDT.S130568","article-title":"Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies","volume":"11","author":"Yang","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib41","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1038\/s41598-021-83099-y","article-title":"Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system","volume":"11","author":"Wu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115149_bib42","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","article-title":"Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury","volume":"91","author":"Xie","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2023.115149_bib43","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s10157-021-02066-z","article-title":"Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury","volume":"25","author":"Hatakeyama","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12882-016-0325-4","article-title":"Proton pump inhibitors are associated with increased risk of development of chronic kidney disease","volume":"17","author":"Arora","year":"2016","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.biopha.2023.115149_bib45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MCG.0000000000001035","article-title":"The association between proton pump inhibitor use with acute kidney injury and chronic kidney disease","volume":"52","author":"Kamal","year":"2018","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.115149_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101464","article-title":"Molecular pathways driving omeprazole nephrotoxicity","volume":"32","author":"Fontecha-Barriuso","year":"2020","journal-title":"Redox Biol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115149_bib47","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1681\/ASN.2015121377","article-title":"Proton pump inhibitors and risk of incident CKD and progression to ESRD","volume":"27","author":"Xie","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115149_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229344","article-title":"Omeprazole use and risk of chronic kidney disease evolution","volume":"15","author":"Guedes","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.115149_bib49","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","article-title":"Association between proton pump inhibitor use and risk of progression of chronic kidney disease","volume":"153","author":"Klatte","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.biopha.2023.115149_bib51","article-title":"Effect of proton pump inhibitors on the risk of chronic kidney disease: a propensity score-based overlap weight analysis using the United Kingdom Biobank","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115149_bib52","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/bcp.14713","article-title":"E. Chronic Kidney Disease-Renal, G. Information Network Study, Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study","volume":"87","author":"Liabeuf","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/fampra\/cmx102","article-title":"Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study","volume":"35","author":"Hung","year":"2018","journal-title":"Fam. Pract."},{"issue":"10","key":"10.1016\/j.biopha.2023.115149_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204231","article-title":"Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort","volume":"13","author":"Rodriguez-Poncelas","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.biopha.2023.115149_bib55","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s10620-017-4725-5","article-title":"Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis","volume":"62","author":"Wijarnpreecha","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2023.115149_bib56","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s11255-018-1908-8","article-title":"The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis","volume":"50","author":"Sun","year":"2018","journal-title":"Int. Urol. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115149_bib57","doi-asserted-by":"crossref","first-page":"462","DOI":"10.23736\/S2724-6051.21.04116-3","article-title":"Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease","volume":"73","author":"Vengrus","year":"2021","journal-title":"Minerva Urol. Nephrol."},{"key":"10.1016\/j.biopha.2023.115149_bib58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ndt\/gfw470","article-title":"The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis","volume":"33","author":"Nochaiwong","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"issue":"6","key":"10.1016\/j.biopha.2023.115149_bib59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.clinthera.2018.04.013","article-title":"Potential adverse drug events and nephrotoxicity related to prophylaxis with omeprazole for digestive disorders: a prospective cohort study","volume":"40","author":"Varallo","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2023.115149_bib60","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s40620-020-00952-5","article-title":"Analysis of the association between emergency dialysis start in patients with end-stage kidney disease and non-steroidal anti-inflammatory drugs, proton-pump inhibitors, and iodinated contrast agents","volume":"34","author":"P\u00e9tureau","year":"2021","journal-title":"J. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041543","article-title":"Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study","volume":"11","author":"Ikuta","year":"2021","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.biopha.2023.115149_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207561","article-title":"Correction: Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.115149_bib63","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1365-2125.1999.00914.x","article-title":"Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism","volume":"47","author":"Tateishi","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115149_bib64","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01213011-200512000-00003","article-title":"Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status","volume":"15","author":"Ieiri","year":"2005","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.biopha.2023.115149_bib65","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2125.2003.02047.x","article-title":"Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115149_bib66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jphs.2019.03.001","article-title":"Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype","volume":"139","author":"Kamiya","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2023.115149_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1067\/mcp.2002.121788","article-title":"ow daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)","volume":"71","author":"Christensen","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib68","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib69","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00004714-200104000-00007","article-title":"Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers","volume":"21","author":"Harvey","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib70","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","article-title":"Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A","volume":"45","author":"Desta","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2023.115149_bib71","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ajt.13935","article-title":"Head-to-head pharmacokinetic comparison of All FK-506 (Tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study","volume":"17","author":"Tremblay","year":"2017","journal-title":"Am. J. Transpl."},{"issue":"6","key":"10.1016\/j.biopha.2023.115149_bib72","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/INF.0000000000003898","article-title":"Boosting of voriconazole levels with omeprazole, A CYP450 2C19 inhibitor","volume":"42","author":"Hsu","year":"2023","journal-title":"Pedia Infect. Dis. J."},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2023.115149_bib74","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/FPC.0000000000000478","article-title":"Investigation of pharmacologic interactions between omeprazole and tacrolimus in a membranous nephropathy patient with CYP3A5 nonexpresser: a case report","volume":"32","author":"Li","year":"2022","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.biopha.2023.115149_bib75","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0022-3565(24)37072-7","article-title":"Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples","volume":"283","author":"Yamazaki","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2023.115149_bib76","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/S0041-1345(02)03409-7","article-title":"Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation","volume":"34","author":"Itagaki","year":"2002","journal-title":"Transpl. Proc."},{"issue":"3","key":"10.1016\/j.biopha.2023.115149_bib77","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1399-0012.2002.01012.x","article-title":"Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study","volume":"16","author":"Logan","year":"2002","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.biopha.2023.115149_bib78","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00508-021-01834-x","article-title":"Is there a correlation between hypomagnesemia linked to long-term proton pump inhibitor use and the active agent?","volume":"134","author":"Ayd\u0131n Yoldemir","year":"2022","journal-title":"Wien. Klin. Wochencgr."},{"issue":"5","key":"10.1016\/j.biopha.2023.115149_bib79","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7150\/ijms.4397","article-title":"Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System","volume":"9","author":"Tamura","year":"2012","journal-title":"Int J. Med. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2023.115149_bib80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/dtb.2021.235385rep","article-title":"Republished: omeprazole-induced hypomagnesaemia, causing renal tubular acidosis with hypokalaemia, hypocalcaemia, hyperlactacidaemia and hyperammonaemia","volume":"59","author":"Isse","year":"2021","journal-title":"Drug Ther. Bull."},{"issue":"11","key":"10.1016\/j.biopha.2023.115149_bib81","article-title":"Hypomagnesaemia - one cause to remember!","volume":"9","author":"Viegas","year":"2022","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"10.1016\/j.biopha.2023.115149_bib82","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/jrms.JRMS_637_18","article-title":"Electrolyte disturbances in children receiving omeprazole for gastroesophageal reflux disease","volume":"25","author":"Famouri","year":"2020","journal-title":"J. Res. Med. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115149_bib83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2009.11.019","article-title":"A case series of proton pump inhibitor-induced hypomagnesemia","volume":"56","author":"Hoorn","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.biopha.2023.115149_bib84","doi-asserted-by":"crossref","first-page":"1092476","DOI":"10.3389\/fphar.2023.1092476","article-title":"Proton-pump inhibitor use amongst patients with severe hypomagnesemia","volume":"14","author":"Seah","year":"2023","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.biopha.2023.115149_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112558","article-title":"The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis","volume":"9","author":"Park","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib86","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5500\/wjt.v9.i2.35","article-title":"Proton pump inhibitors and adverse effects in kidney transplant recipients: a meta-analysis","volume":"9","author":"Boonpheng","year":"2019","journal-title":"World J. Transpl."},{"key":"10.1016\/j.biopha.2023.115149_bib87","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/ndt\/gfh831","article-title":"Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity","volume":"20","author":"Holzmacher","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"issue":"12","key":"10.1016\/j.biopha.2023.115149_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122162","article-title":"Proton-pump inhibitors and hypomagnesaemia in kidney transplant recipients","volume":"8","author":"Douwes","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2023.115149_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.947899","article-title":"Mass spectrometric analysis of TRPM6 and TRPM7 from small intestine of omeprazole-induced hypomagnesemic rats","volume":"12","author":"Kampuang","year":"2022","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115149_bib90","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00424-013-1306-0","article-title":"Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6","volume":"465","author":"Lameris","year":"2013","journal-title":"Pflug. Arch."},{"issue":"4","key":"10.1016\/j.biopha.2023.115149_bib91","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13846","article-title":"Mechanisms of proton pump inhibitor-induced hypomagnesemia","volume":"235","author":"Gommers","year":"2022","journal-title":"Acta Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115149_bib92","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/07435800.2015.1094088","article-title":"Hypomagnesemia linked to new-onset diabetes mellitus after kidney transplantation: A systematic review and meta-analysis","volume":"41","author":"Cheungpasitporn","year":"2016","journal-title":"Endocr. Res."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222300940X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222300940X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:18:36Z","timestamp":1782371916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222300940X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":92,"alternative-id":["S075333222300940X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115149","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients \u2013 A review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115149"}}